Exit from arsenite-induced mitotic arrest is p53 dependent

Environmental Health Perspectives

Volumn 114, Issue 9, 2006, Pages 1401-1406

  McNeely, Samuel C ^a   Xu, Xiaogiang ^a   Taylor, B Frazier ^a   Zacharias, Wolfgang ^a,b   McCabe Jr , Michael J ^c   States, J Christopher ^a,b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

Author keywords

Apoptosis; Arsenite; ID1; Microarray; Mitotic arrest; p53

Indexed keywords

ARSENITE SODIUM; CARCINOGEN; INHIBITOR OF DNA BINDING 1 PROTEIN; MESSENGER RNA; PROTEIN DERIVATIVE; PROTEIN P53; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CARCINOGENICITY; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL KINETICS; CELL PROTECTION; CELL SYNCHRONIZATION; CHEMICAL CARCINOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOBLOTTING; MICROARRAY ANALYSIS; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY MECHANISM; SENSITIVITY ANALYSIS; TRANSCRIPTION REGULATION; WESTERN BLOTTING;

APOPTOSIS; ARSENITES; BENZIMIDAZOLES; CELL CYCLE; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; G2 PHASE; GENES, P53; HUMANS; INHIBITOR OF DIFFERENTIATION PROTEIN 1; KINETICS; MICROARRAY ANALYSIS; MITOSIS; RNA, MESSENGER; SODIUM COMPOUNDS; TIME FACTORS;

EID: 33748174623     PISSN: 00916765     EISSN: 15529924     Source Type: Journal    
DOI: 10.1289/ehp.8969     Document Type: Article

References (42)

1. Abraham NG. 2003. Therapeutic applications of human heme oxygenase gene transfer and gene therapy. Curr Pharm Des 9:2513-2524.
2. Adimoolam S, Ford JM. 2002. p53 and DNA damage-inducible expression of the xeroderma pigmentosum group C gene. Proc Natl Acad Sci USA 99:12985-12990.
3. 1, cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. Proc Natl Acad Sci USA 92:8493-8497.
4. Alani RM, Hasskarl J, Grace M, Hernandez MC, Israel MA, Munger K. 1999. Immortalization of primary human keratinocytes by the helix-loop-helix protein, Id-1. Proc Natl Acad Sci USA 96:9637-9641.
5. Andrew AS, Warren AJ, Barchowsky A, Temple KA, Klei L, Soucy NV, et al. 2003. Genomic and proteomic profiling of responses to toxic metals in human lung cells. Environ Health Perspect 111:825-835.
6. Chen F, Zhang Z, Bower J, Lu Y, Leonard SS, Ding M, et al. 2002. Arsenite-induced Cdc25C degradation is through the KENbox and ubiquitin-proteasome pathway. Proc Natl Acad Sci USA 99:1990-1995.
7. Chen H, Liu J, Merrick BA, Waalkes MP. 2001. Genetic events associated with arsenic-induced malignant transformation: applications of cDNA microarray technology. Mol Carcinog 30:79-87.
8. Cohen MH, Hirschfeld S, Flamm HS, Ibrahim A, Johnson JR, Leary JJ, et al. 2001. Drug approval summaries: Arsenic inoxide, tamoxifen citrate, anastrazole, paclitaxel, bexarotene. Oncologist 6:4-11.
9. Davison K, Mann KK, Waxman S, Miller WH, Jr, 2004, JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood 103:3496-3502.
10. Du YH, Ho PC. 2001. Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and -resistant gynecological cancer cell lines. Cancer Chemother Pharmacol 47:481-490.
11. Erenpreisa J, Cragg MS. 2001, Mitotic death: a mechanism of survival? A review. Cancer Cell Int 1:1. Available: hitp://www.cancerci.com/content/ 1/1/1 [accessed 9 August 2006].
12. Ford JM, Hanawalt PC. 1997. Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts, J Biol Chem 272:28073-28080.
13. Halicka HD, Smolewski P, Darzynkiewcz Z, Dai W, Traganos F. 2002, Arsenic trioxide arrests cells early in mitosis leading to apoptosis. Cell Cycle 1:201-209
14. Hasskarl J, Duensing S, Manuel E, Munger K 2004. The helix-loop-helix protein ID1 localizes to centrosomes and rapidly induces abnormal centrosome numbers. Oncogene 23:1930-1938.
15. Huang SC, Lee TC. 1998. Arsenite inhibits mitotic division and perturbs spindle dynamics in HeLa S3 cells. Carcinogonesis 19:889-896.
16. Jiang G, Gong Z, Li XF, Cullen WR, Le XC. 2003. Interaction of trivalent arsenicals with meta metallothionein. Chem Res Toxicol 16:873-880.
17. Jin S, Levine AJ. 2001. The p53 functional circuit. J Cell Sci 114: 4139-4140.
18. Kuhholzer B, Prather RS. 2001. Synchronization of porcine fetal fibroblast cells wilh topoisomerase-inhibitor Hoechst 33342. Anim Reprod Sci 66:109-116.
19. Li J, Gorospe M, Hutter D, Barnes J, Keyse SM, Liu Y. 2001. Transcriptional induction of MKP-1 in response to stress is associated with histone H3 phosphorylation-acetylation. Mol Cell Biol 21:8213-8224.
20. Li M, Zhou JY, Ge Y, Matherly LH, Wu GS. 2003. The phosphatase MKP1 is a transcriptional target of p53 involved in cell cycle regulation. J Biol Chem 278:41059-41068.
21. Ling MT, Wang X, Ouyang XS, Xu K, Tsao SW, Wong YC. 2003. Id-1 expression promotes cell survival through activation of NF-kappaB signalling pathway in prostate cancer cells. Oncogene 22:4498-4508.
22. Liu J, Kadiiska MB, Liu Y, Lu T, Qu W, Waalkes MP. 2001. Stress-related gene expression in mice treated with inorganic arsenicals. Toxicol Sci 61:314-320.
23. Liu J, Liu Y, Goyer RA, Achanzar W, Waalkes MP. 2000. Metallothionein-I/ II null mice are more sensitive than wild-type mice to the hepatotoxic and nephrotoxic effects of chronic oral or injected inorganic arsenicals. Toxicol Sci 55:460-467.
24. Lloyd OR, Hanawalt PC. 2002. p53 controls global nucleotide excision repair of low levels of structurally diverse henzo(g)chrysene-DNA adducts in human fibroblasts. Cancer Res 62:5288-5294.
25. 3) in the orthotopic metastasis model of androgen-independent prostate cancer. Cancer Res 61:5432-5440.
26. McCabe MJ Jr, Singh KP, Reddy SA, Chelladurai B, Pounds JG, Reiners JJ Jr, et al. 2000. Sensitivity of myelomonocytic leukemia cells to arsenite-induced cell cycle disruption, apoptosis, and enhanced differentiation is dependent on the inter-relationship between arsenic concentration, duration of treatment, and cell cycle phase. J Pharmacol Exp Ther 295:724-733.
27. 2/M arrest in U937 myeloid leukemia cells. J Pharmacol Exp Ther 313:877-887
28. NRC (National Research Council). 1999. Arsenic in Drinking Water. Washington DC:National Academy Press.
29. NRC (National Research Council). 2001. Arsenic in Drinking Water: 2001 Update. Washington DC:National Academy Press.
30. 2/M growth arrest and apoptosis after caspase-3 activation and bcl-2 phosphorylation in promonocytic U937 cells. Biochem Biophys Res Commun 286:726-734.
31. Robles Al, Bemmels NA, Foraker AB, Harris CC. 2001. APAF-1 is a transcriptional target of p53 in DNA damage-induced apoptosis. Cancer Res 61:6660-6664.
32. Sikder HA, Devlin MK, Dunlap S, Ryu B, Alani RM, 2003. Id proteins in cell growth and tumorigenesis. Cancer Cell 3:525-530.
33. States JC, Reiners JJ Jr, Pounds JG, Kaplan DJ, Beauerle BD, McNeely SC, at al. 2002. Arsenite disrupts mitosis and induces apoptosis in SV40-transformed human skin fibroblasts. Toxicol Appl Pharmacol 180:83-91.
34. CIPI/WAF1. J Pharmacol Exp Ther 318:142-151.
35. Taylor WR, Schonthal AH, Galante J, Stark GR. 2001. p130/E2F4 binds to and represses the cdc2 promoter in response to p53. J Biol Chem 276:1998-2006.
36. 2/M transition by p53. Oncogene 20:1803-1815.
37. 2 synchrony in cultured rodent and human diploid fibroblasts. Proc Natl Acad Sci USA 87: 5104-5108.
38. Uslu R, Sanli UA, Sezgin C, Karabulut B, Terzioglu E, Omay SB, at al. 2000. Arsenic trioxide-madiated cytotoxicity and apoptosis in prostate and ovarian carcinoma cell lines. Clin Cancer Res 6:4957-4964.
39. Vega L, Gonsebatt ME, Ostrosky-Wegman P. 1995. Aneugenic effect of sodium arsenite on human lymphocytes in vitro: an individual susceptibility effect detected. Mutat Res 334:365-373.
40. Yih LH, Ho IC, Lee TC. 1997. Sodium arsenite disturbs mitosis and induces chromosome loss in human fibroblasts. Cancer Res 57:5051-5059.
41. Yih LH, Lee TC. 2000. Arsenite induces p53 accumulation through an ATM-dependent pathway in human fibroblasts. Cancer Res 60:6346-6352
42. Yin Y, Tainsky MA, Bischoff FZ, Strong LC, Wahl GM. 1992. Wildtype p53 restores cell cycle control and inhibits gene amplification in cells with mutant p53 alleles. Cell 70:937-948.